- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT00125034
Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer (mCRC) (OPUS)
Open, Randomized, Controlled, Multicenter Phase II Study Comparing 5-FU/FA Plus Oxaliplatin (FOLFOX-4) Plus Cetuximab Versus 5-FU/FA Plus Oxaliplatin (FOLFOX-4) as First-line Treatment for Epidermal Growth Factor Receptor-expressing Metastatic Colorectal Cancer
Обзор исследования
Статус
Вмешательство/лечение
Тип исследования
Регистрация (Действительный)
Фаза
- Фаза 2
Контакты и местонахождение
Места учебы
-
-
-
Graz, Австрия
- Research Site
-
Linz, Австрия
- Research Site
-
Salzburg, Австрия
- Research Site
-
Wien, Австрия
- Research Site
-
Zams, Австрия
- Research Site
-
-
-
-
-
Antwerpen, Бельгия
- Research Site
-
Bonheiden, Бельгия
- Research Site
-
Brugge, Бельгия
- Research Site
-
Hasselt, Бельгия
- Research Site
-
Leuven, Бельгия
- Research Site
-
Roeselare, Бельгия
- Research Site
-
Turnhout, Бельгия
- Research Site
-
ZU Gent, Бельгия
- Research Site
-
-
-
-
-
Aschaffenburg, Германия
- Research Site
-
Dresden, Германия
- Research Site
-
Essen, Германия
- Research Site
-
Hamburg, Германия
- Research Site
-
Kiel, Германия
- Research Site
-
Magdeburg, Германия
- Research Site
-
Mannheim, Германия
- Research Site
-
Nürnberg, Германия
- Research Site
-
Tübingen, Германия
- Research Site
-
-
-
-
-
Athens, Греция
- Research Site
-
Loannina, Греция
- Research Site
-
Thessaloniki, Греция
- Research Site
-
-
-
-
-
Haifa, Израиль
- Research Site
-
Kfar-Saba, Израиль
- Research Site
-
Petah Tiqva, Израиль
- Research Site
-
Rehovot, Израиль
- Research Site
-
Tel-Aviv, Израиль
- Research Site
-
Tel-Hashomer, Израиль
- Research Site
-
-
-
-
-
Bilbao, Испания
- Research Site
-
Burgos, Испания
- Research Site
-
Girona, Испания
- Research Site
-
Madrid, Испания
- Research Site
-
Malaga, Испания
- Research Site
-
Orense, Испания
- Research Site
-
Reus, Испания
- Research Site
-
Valencia, Испания
- Research Site
-
-
-
-
-
Brescia, Италия
- Research Site
-
Milano, Италия
- Research Site
-
Padova, Италия
- Research Site
-
Pavia, Италия
- Research Site
-
Rome, Италия
- Research Site
-
Torino, Италия
- Research Site
-
-
-
-
-
Bialystok, Польша
- Research Site
-
Krakow, Польша
- Research Site
-
Lublin, Польша
- Research Site
-
Opole, Польша
- Research Site
-
Poznan, Польша
- Research Site
-
Szczecin, Польша
- Research Site
-
Warszawa, Польша
- Research Site
-
-
-
-
-
Lisbon, Португалия
- Research Site
-
Santa Maira da Feira, Португалия
- Research Site
-
-
-
-
-
Kazan, Российская Федерация
- Research Site
-
Krasnodar, Российская Федерация
- Research Site
-
Moscow, Российская Федерация
- Research Site
-
Obninsk, Российская Федерация
- Research Site
-
Samara, Российская Федерация
- Research Site
-
St. Petersburg, Российская Федерация
- Research Site
-
-
-
-
-
Alba Iulia, Румыния
- Research Site
-
Bucurest, Румыния
- Research Site
-
Onesti, Румыния
- Research Site
-
Oradea, Румыния
- Research Site
-
Timisoara, Румыния
- Research Site
-
-
-
-
-
Dnepropetrovsk, Украина
- Research Site
-
Kharkov, Украина
- Research Site
-
Kiev, Украина
- Research Site
-
Lviv, Украина
- Research Site
-
Simferopol, Украина
- Research Site
-
Vinnitsa, Украина
- Research Site
-
-
-
-
-
Besancon, Франция
- Research Site
-
Clermond Ferrand, Франция
- Research Site
-
Clichy, Франция
- Research Site
-
Montpellier, Франция
- Research Site
-
Paris, Франция
- Research Site
-
Rouen, Франция
- Research Site
-
Strasbourg, Франция
- Research Site
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- First-line mCRC
- EGFR positive
- Bi-dimensional measurable index lesion
Exclusion Criteria:
- Previous exposure to EGFR-targeting therapy
- Previous oxaliplatin-based therapy
- Previous chemotherapy for colorectal cancer except adjuvant treatment with progression of disease documented > 6 months after end of adjuvant treatment
- Radiotherapy
- Surgery
- Any other investigational drug in the 30 days before randomization
- Brain metastasis and/or leptomeningeal disease
- Acute or sub-acute intestinal occlusion or history of inflammatory bowel disease
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
---|---|
Экспериментальный: Cetuximab Plus FOLFOX-4
|
Cetuximab will always be administered first, followed by oxaliplatin at least 1 hour later. Following completion of the oxaliplatin infusion or simultaneously with oxaliplatin folinic acid (FA) will be administered (at a dose of 200 mg/m^2, infused over 120 minutes, on day 1 and day 2, every two weeks) and then 5-Fluorouracil (5-FU) (as a bolus of 400 mg/m^2/day intravenously (IV) over 2-4 minutes followed by 600 mg/m^2/day infused over 22-hour, on day 1 and day 2, every two weeks). Until progression or unacceptable toxicity develops |
Активный компаратор: FOLFOX-4 Alone
|
Oxaliplatin will always be administered first or simultaneously with FA (at a dose of 200 mg/m^2, infused over 120 minutes, on day 1 and day 2, every two weeks) and then 5-FU (as a bolus of 400 mg/m^2/day IV over 2-4 minutes followed by 600 mg/m^2/day infused over 22-hour, on day 1 and day 2, every two weeks). Until progression or unacceptable toxicity develops |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
---|---|---|
Best Overall Response Rate - Independent Review Committee (IRC)
Временное ограничение: Evaluations were performed every 6 weeks until progression, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 4 August 2006
|
The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified World Health Organisation (WHO) criteria) as assessed by an IRC.
|
Evaluations were performed every 6 weeks until progression, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 4 August 2006
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
---|---|---|
Best Overall Response Rate (Chinese V-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Wild-Type Population)
Временное ограничение: Evaluations were performed every 6 weeks until progression, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 1 Mar 2007
|
The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified WHO criteria) as assessed by an IRC.
|
Evaluations were performed every 6 weeks until progression, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 1 Mar 2007
|
Best Overall Response Rate (KRAS Mutant Population)
Временное ограничение: Evaluations were performed every 6 weeks until progression, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 1 Mar 2007
|
The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified WHO criteria) as assessed by an IRC.
|
Evaluations were performed every 6 weeks until progression, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 1 Mar 2007
|
Progression-free Survival Time
Временное ограничение: Time from randomisation to disease progression, death or last tumour assessment, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 01 Mar 2007
|
Duration from randomization until radiological progression as assessed by an IRC (based on modified WHO criteria) or death due to any cause. Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment. |
Time from randomisation to disease progression, death or last tumour assessment, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 01 Mar 2007
|
Progression-free Survival Time (KRAS Wild-Type Population)
Временное ограничение: Time from randomisation to disease progression, death or last tumour assessment, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 30 Nov 2008
|
Duration from randomization until radiological progression as assessed by an IRC (based on modified WHO criteria) or death due to any cause. Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment. |
Time from randomisation to disease progression, death or last tumour assessment, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 30 Nov 2008
|
Progression-free Survival Time (KRAS Mutant Population)
Временное ограничение: Time from randomisation to disease progression, death or last tumour assessment, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 30 Nov 2008
|
Duration from randomization until radiological progression as assessed by an IRC (based on modified WHO criteria) or death due to any cause. Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment. |
Time from randomisation to disease progression, death or last tumour assessment, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 30 Nov 2008
|
Overall Survival Time
Временное ограничение: Time from randomisation to death or last day known to be alive, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 30 Nov 2008
|
Time from randomization to death.
Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier.
|
Time from randomisation to death or last day known to be alive, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 30 Nov 2008
|
Overall Survival Time (KRAS Wild-Type Population)
Временное ограничение: Time from randomisation to death or last day known to be alive, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 30 November 2008
|
Time from randomization to death.
Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier.
|
Time from randomisation to death or last day known to be alive, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 30 November 2008
|
Overall Survival Time (KRAS Mutant Population)
Временное ограничение: Time from randomisation to death or last day known to be alive, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 30 November 2008
|
Time from randomization to death.
Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier.
|
Time from randomisation to death or last day known to be alive, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 30 November 2008
|
Participants With No Residual Tumor After Metastatic Surgery
Временное ограничение: Time from first dose up to 30 days after the last dose of study treatment, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 30 November 2008
|
No residual tumor after on-study surgery for metastases.
|
Time from first dose up to 30 days after the last dose of study treatment, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 30 November 2008
|
Disease Control Rate (Cut Off Date 4 August 2006)
Временное ограничение: Evaluations were performed every 6 weeks until progression, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 4 August 2006
|
The disease control rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response + Stable Disease as best overall response according to radiological assessments as assessed by IRC (based on modified WHO criteria).
|
Evaluations were performed every 6 weeks until progression, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 4 August 2006
|
Duration of Response
Временное ограничение: Time from first assessment of Complete Response or Partial Response to disease progression,death or last tumor assessment, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 01 Mar 2007
|
Time from first assessment of Complete Response or Partial Response to disease progression or death (within 60 days of last tumor assessment). Patients without event are censored on the date of last tumor assessment. Tumor assessments based on modified WHO criteria. |
Time from first assessment of Complete Response or Partial Response to disease progression,death or last tumor assessment, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 01 Mar 2007
|
Safety - Number of Patients Experiencing Any Adverse Event
Временное ограничение: time from first dose up to 30 after last dose of study treatment, reported between day of first patient dose of study treatment, 27 Jul 2005, until cut-off date 30 Nov 2008
|
Please refer to Adverse Events section for further details
|
time from first dose up to 30 after last dose of study treatment, reported between day of first patient dose of study treatment, 27 Jul 2005, until cut-off date 30 Nov 2008
|
Соавторы и исследователи
Спонсор
Следователи
- Главный следователь: Bokemeyer, Prof. Dr., Klinik für Onkologie, Hämatologie und Knochenmarktransplantationen Universitätsklinikum Hamburg-Eppendorf, Germany
Публикации и полезные ссылки
Общие публикации
- Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A, Koralewski P. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009 Feb 10;27(5):663-71. doi: 10.1200/JCO.2008.20.8397. Epub 2008 Dec 29.
- Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A, Celik I, Schlichting M, Koralewski P. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol. 2011 Jul;22(7):1535-1546. doi: 10.1093/annonc/mdq632. Epub 2011 Jan 12.
Даты записи исследования
Изучение основных дат
Начало исследования
Первичное завершение (Действительный)
Завершение исследования (Действительный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Оценивать)
Обновления учебных записей
Последнее опубликованное обновление (Оценивать)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
- Заболевания пищеварительной системы
- Патологические процессы
- Новообразования
- Новообразования по локализации
- Желудочно-кишечные новообразования
- Новообразования пищеварительной системы
- Желудочно-кишечные заболевания
- Заболевания толстой кишки
- Кишечные заболевания
- Новообразования кишечника
- Заболевания прямой кишки
- Неопластические процессы
- Колоректальные новообразования
- Метастаз новообразования
- Противоопухолевые агенты
- Противоопухолевые агенты, иммунологические
- Оксалиплатин
- Цетуксимаб
Другие идентификационные номера исследования
- EMR 62202-047
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .
Клинические исследования Cetuximab
-
Associazione Volontari Pazienti OncologiciMario Negri Institute for Pharmacological ResearchЗавершенныйПлоскоклеточный рак головы и шеиИталия